EWS & EVENTS
Agonist Redirected Checkpoint Platform (ARC); Engineering Bi-Functional Fusion Proteins (SIRPα-Fc-CD40L), for Cancer Immunotherapy

SITC 2018

2018_SITC_k_SIRPa
MIGHT ALSO LIKE
YOU MIGHT ALSO LIKE
Shattuck Labs, Inc. Announces Initiation of Phase 1 Clinical Trial of SL-279252 (PD1/OX40L)

Shattuck Labs Press Release May 6, 2019  

Read more
Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy

Fromm et.al Journal for ImmunoTherapy of Cancer, 18 December 2018

Read more